Valneva SE, a prophylactic vaccine for infectious diseases developer, raised $94 million by offering 3.5 million ADSs at $26.41, within the proposed range of $24.04 to $28.85.
The company is a specialty vaccine company focused on developing and commercializing prophylactic vaccines for infectious diseases with significant unmet medical needs. They targeted an approach to vaccine development, beginning with the identification of deadly and debilitating infectious diseases that lack a prophylactic vaccine solution and for which there are limited therapeutic treatment options.
The Saint-Herblain, France-based company was founded in 1999 and booked $131 million in sales for the 12 months ended December 31, 2020. It plans to list on the Nasdaq Global Market under the symbol “VALN.” Goldman Sachs, Jefferies, Guggenheim Securities and Bryan, Garnier & Co are underwriters of the IPO.
The company engages Cooley LLP as US Securities Counsel, and PricewaterhouseCoopers LLP as Independent Auditor.
#ipo #Nasdaq #vaccine #infection #Valneva
Hexcellence Consulting has experienced IPO consulting team focus on listing in US Stock Market,
namely NYSE, Nasdaq and OTC Markets.
Should you interested to list your company in US Stock Market,
please contact us at [email protected]